Hello, my wonderful readers! Zydus Cadila started supplying its Covid-19 vaccine ZyCoV-D about 6 months after it was authorized for emergency use in the 12 and above age group. According to “rajkotupdates.news : zydus needle free corona vaccine zycov d, “ZyCoV-D is a three-dose vaccine administered intradermally using the painless PharmaJet needle-free system, Tropis, on day 0, day 28, and day 56. Each jab costs Rs 265 plus Rs 93 for the needle-free applicator. In this blog, we are going talk extensively about the product.
Therefore a brief training session will be provided to frontline staff and vaccine administrators on how to use the needle-free pharma jet application in practical field settings for the adult population. The only vaccine currently being given to children is Covaxin, though two more shots (Covovax and Corbevax) will be available once they have been approved for emergency use in 2021 by India’s Drug Controller General.
What is the ZyCoV-D COVID19 Vaccine
The ZyCoV-D vaccine was developed in India and is the first DNA-based COVID-19 vaccine to be given to humans, including children and adults 12 years of age and older. So, the vaccine was developed in association with the Department of Biotechnology (DBT) and is being distributed under the banner of “Mission COVID Suraksha,” which is being run by BIRAC, a PSU of DBT. So, no DNA vaccines have been authorized for use in humans as of yet. But several DNA vaccines are currently undergoing human clinical trials, and we regulatory agencies have already given a few DNA vaccines the green light. The vaccine, which is based on DNA plasmid technology, has an efficacy rate of 66.66%. ZyCoV-D was originally a three-dose vaccine that was given three to four weeks apart. Recently it has been approved for a two-dose regimen.
The chemical description
ZyCoV-D is a Plasmid DNA vaccine that, when administered, induces the production of the SARS-CoV-2 virus spike protein. This immune response is mediated by the cellular and humoral arms of the human immune system and is crucial for both disease prevention and viral clearance. The large pharmaceutical corporation, with its head office in Ahmedabad, asserts that the plug-and-play technology of the plasmid DNA platform can be easily modified to handle virus mutations, including those that are already present.
How is the vaccine administered needle free?
The vaccine is administered using needle-free injectors. It is used to inject a tiny stream of fluid through the skin and into the target tissue depth. The company asserts that this technology can eliminate the risk of needlestick injuries while significantly reducing any potential negative effects. Patients with trypanophobia, a condition characterized by an irrational fear of blood or needles, will also benefit from it.
The Drugs Controller General of India (DCGI) received an application from Cadila Healthcare on July 1st, 2021. Therefore it requested authorization to use the vaccine only for specific, time-sensitive emergencies. The CDSCO Subject Expert Committee recommended that the DCGI approve the request on August 20, 2021.
Production of the ZyCoV-D vaccine, with an annual capacity of 240 million doses, began on April 23, 2021.
ZyCoV-D is India’s first DNA Vaccine for the COVID-19 virus. “rajkotupdates.news : zydus needle free corona vaccine zycov d” reported on it and talked about how revolutionary it is. So we talked about what ZyCoV-D is, its chemical description in simple terms, and how the vaccine is administered. Additionally, we also talked about the authorizations it received and its deployment. The take of “rajkotupdates.news : zydus needle free corona vaccine zycov d” on ZyCoV-D was expanded in this blog.
If you want to read blogs similar to this, click here